Dr. Pamela Munster, a medical oncologist at UCSF and the founder of Alessa Therapeutics commented, “All of us at Alessa are grateful for the efforts of the NCI team and the patients’ willingness to participate in the company’s first clinical study in the United States. As an oncologist and a cancer researcher, I strive every day to deliver the most effective treatment while minimizing side effects. Through this study, we hope to understand the potential of our novel approach to improve the quality of life for men indicated for ADT and radiation therapy in the treatment of prostate cancer.”
